Literature DB >> 30042223

Complications of Immunosuppression in Glomerular Disease.

J Ashley Jefferson1.   

Abstract

Most glomerular diseases are immunologically mediated disorders of the kidney and are common causes of ESKD. In addition to supportive therapy, a wide range of immunosuppressive agents are used in the management of patients with these conditions. Immunosuppression requires a careful balance of risk and benefits, and many of these agents have a narrow therapeutic window and require close monitoring. This review describes the side effects of immunosuppressive agents used in recent randomized, controlled trials of glomerular disease, and highlights some of the key adverse events that determine the choice and prescription of these medications.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  ANCA; IgA nephropathy; Immunosuppressive Agents; Kidney Failure, Chronic; adverse events; cyclophosphamide; glomerular disease; glomerulonephritis; glucocorticoids; immunosuppression; kidney; lupus nephritis; membranous nephropathy; mycophenolate mofetil; rituximab; tacrolimus

Year:  2018        PMID： 30042223      PMCID： PMC6086710          DOI： 10.2215/CJN.01920218

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


  76 in total

1.  Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.

Authors:  Wen-Ling Ye; Nan Tang; Yu-Bing Wen; Hang Li; Min-Xi Li; Bin Du; Xue-Mei Li
Journal:  Int Urol Nephrol       Date:  2016-06-28       Impact factor: 2.370

2.  Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Authors:  Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2012-11

3.  Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.

Authors:  Emma E van Daalen; Raffaella Rizzo; Andreas Kronbichler; Ron Wolterbeek; Jan A Bruijn; David R Jayne; Ingeborg M Bajema; Chinar Rahmattulla
Journal:  Ann Rheum Dis       Date:  2016-11-29       Impact factor: 19.103

4.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

5.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

6.  Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.

Authors:  D T Boumpas; H A Austin; E M Vaughan; C H Yarboro; J H Klippel; J E Balow
Journal:  Ann Intern Med       Date:  1993-09-01       Impact factor: 25.391

Review 7.  Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.

Authors:  William E Monaco; Jonathan D Jones; William F C Rigby
Journal:  Clin Rheumatol       Date:  2016-05-21       Impact factor: 2.980

8.  Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Authors:  William F Pendergraft; Frank B Cortazar; Julia Wenger; Andrew P Murphy; Eugene P Rhee; Karen A Laliberte; John L Niles
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-13       Impact factor: 8.237

9.  Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Authors:  Jicheng Lv; Hong Zhang; Muh Geot Wong; Meg J Jardine; Michelle Hladunewich; Vivek Jha; Helen Monaghan; Minghui Zhao; Sean Barbour; Heather Reich; Daniel Cattran; Richard Glassock; Adeera Levin; David Wheeler; Mark Woodward; Laurent Billot; Tak Mao Chan; Zhi-Hong Liu; David W Johnson; Alan Cass; John Feehally; Jürgen Floege; Giuseppe Remuzzi; Yangfeng Wu; Rajiv Agarwal; Hai-Yan Wang; Vlado Perkovic
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

10.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
View more
  19 in total

1.  Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers.

Authors:  Simon A Carter; Talia Gutman; Charlotte Logeman; Dan Cattran; Liz Lightstone; Arvind Bagga; Sean J Barbour; Jonathan Barratt; John Boletis; Dawn Caster; Rosanna Coppo; Fernando C Fervenza; Jürgen Floege; Michelle Hladunewich; Jonathan J Hogan; A Richard Kitching; Richard A Lafayette; Ana Malvar; Jai Radhakrishnan; Brad H Rovin; Nicole Scholes-Robertson; Hérnan Trimarchi; Hong Zhang; Karolis Azukaitis; Yeoungjee Cho; Andrea K Viecelli; Louese Dunn; David Harris; David W Johnson; Peter G Kerr; Paul Laboi; Jessica Ryan; Jenny I Shen; Lorena Ruiz; Angela Yee-Moon Wang; Achilles Hoi Kan Lee; Samuel Fung; Matthew Ka-Hang Tong; Armando Teixeira-Pinto; Martin Wilkie; Stephen I Alexander; Jonathan C Craig; Allison Tong
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-30       Impact factor: 8.237

2.  Commentary on Complications of Immunosuppressive Treatments for Glomerulonephritis.

Authors:  Bryan R Kestenbaum; Stephen L Seliger
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-24       Impact factor: 8.237

Review 3.  Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.

Authors:  Jinghong Zhao; Zhihong Liu
Journal:  Pediatr Nephrol       Date:  2019-03-23       Impact factor: 3.714

4.  Effects of hydroxychloroquine on proteinuria in membranous nephropathy.

Authors:  Yan-Jiao Cheng; Xu-Yang Cheng; Yi-Miao Zhang; Fang Wang; Xin Wang; Li-Qiang Meng; Gang Liu; Zhao Cui; Ming-Hui Zhao
Journal:  J Nephrol       Date:  2021-11-30       Impact factor: 3.902

5.  A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder Workshops.

Authors:  Simon A Carter; Liz Lightstone; Dan Cattran; Allison Tong; Arvind Bagga; Sean J Barbour; Jonathan Barratt; John Boletis; Dawn J Caster; Rosanna Coppo; Fernando C Fervenza; Jürgen Floege; Michelle A Hladunewich; Jonathan J Hogan; A Richard Kitching; Richard A Lafayette; Ana Malvar; Jai Radhakrishnan; Brad H Rovin; Nicole Scholes-Robertson; Hernán Trimarchi; Hong Zhang; Samaya Anumudu; Yeoungjee Cho; Talia Gutman; Emma O'Lone; Andrea K Viecelli; Eric Au; Karolis Azukaitis; Amanda Baumgart; Amelie Bernier-Jean; Louese Dunn; Martin Howell; Angela Ju; Charlotte Logeman; Melissa Nataatmadja; Benedicte Sautenet; Ankit Sharma; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-30       Impact factor: 8.237

6.  ANCA Vasculitis Treatment in the Dialysis Patient: Caution Needed!

Authors:  Elizabeth Hendren; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2021-11       Impact factor: 8.237

7.  Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study.

Authors:  Claudius Speer; Christine Altenmüller-Walther; Jan Splitthoff; Christian Nusshag; Florian Kälble; Paula Reichel; Christian Morath; Martin Zeier; Raoul Bergner; Matthias Schaier
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

8.  Overexpressed angiotensin-converting enzyme in neutrophils suppresses glomerular damage in crescentic glomerulonephritis.

Authors:  Suguru Saito; Narihito Tatsumoto; Duo-Yao Cao; Nobuyuki Nosaka; Hiroshi Nishi; Daniel N Leal; Ellen Bernstein; Kenichi Shimada; Moshe Arditi; Kenneth E Bernstein; Michifumi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2022-08-18

9.  Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement.

Authors:  Bogdan Obrișcă; Alexandra Vornicu; Roxana Jurubiță; Camelia Achim; Raluca Bobeică; Andreea Andronesi; Bogdan Sorohan; Vlad Herlea; Alexandru Procop; Constantin Dina; Gener Ismail
Journal:  Clin Rheumatol       Date:  2021-02-17       Impact factor: 2.980

10.  Infectious Complications in Patients with Primary Glomerulonephritis over 10 Years: A Single-Center Experience in Turkey.

Authors:  Rezzan Eren Sadioglu; Sahin Eyupoglu; Siyar Erdogmus; Gizem Kumru Sahin; Fugen Yoruk; Sim Kutlay; Kenan Keven; Sehsuvar Erturk; Sule Sengul
Journal:  Kidney Dis (Basel)       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.